Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report
- PMID: 11118462
- DOI: 10.1200/JCO.2000.18.24.4016
Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report
Abstract
Purpose: To provide an estimate of long-term prognosis for patients with osteosarcoma of the extremity treated in a single institution with neoadjuvant chemotherapy and observed for at least 10 years.
Patients and methods: Patients with nonmetastatic osteosarcoma of the extremity were preoperatively treated with high-dose methotrexate, cisplatin, and doxorubicin (ADM). Postoperatively, good responders (90% or more tumor necrosis) received the same three drugs used before surgery, whereas poor responders (less than 90% tumor necrosis) received ifosfamide and etoposide in addition to those three drugs.
Results: For the 164 patients who entered the study between September 1986 and December 1989, surgery was a limb salvage in 136 cases (82%) and a good histologic response was observed in 117 patients (71%). At a follow-up ranging from 10 to 13 years (median, 11.5 years), 101 patients (61%) remained continuously free of disease, 61 relapsed, and two died of ADM-induced cardiotoxicity. There were no differences in prognosis between good and poor responding patients. ADM-induced cardiotoxicity (six patients), male infertility (10 of the 12 assessable patients), and second malignancies (seven patients) were the major complications of chemotherapy. Despite the large number of limb salvages performed, only four local recurrences (2.4%) were registered.
Conclusion: With an aggressive neoadjuvant chemotherapy, it is possible to cure more than 60% of patients with nonmetastatic osteosarcoma of the extremity and amputation may be avoided in more than 80% of them. Because local or systemic relapses, myocardiopathies, and second malignancies are possible even 5 years or more after the beginning of treatment, a long-term follow-up is recommended for these patients.
Similar articles
-
Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin.Cancer. 1993 Dec 1;72(11):3227-38. doi: 10.1002/1097-0142(19931201)72:11<3227::aid-cncr2820721116>3.0.co;2-c. Cancer. 1993. PMID: 8242546
-
Local and systemic control for osteosarcoma of the extremity treated with neoadjuvant chemotherapy and limb salvage surgery: the Rizzoli experience.Oncol Rep. 2000 Sep-Oct;7(5):1129-33. doi: 10.3892/or.7.5.1129. Oncol Rep. 2000. PMID: 10948351
-
Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities.Clin Orthop Relat Res. 1991 Sep;(270):87-98. Clin Orthop Relat Res. 1991. PMID: 1884564
-
An update of Scandinavian studies of osteosarcoma.Cancer Treat Res. 1993;62:293-8. doi: 10.1007/978-1-4615-3518-8_35. Cancer Treat Res. 1993. PMID: 8096745 Review. No abstract available.
-
Adjuvant and neoadjuvant chemotherapy in osteosarcoma.Chir Organi Mov. 2001 Oct-Dec;86(4):253-68. Chir Organi Mov. 2001. PMID: 12056242 Review. English, Italian.
Cited by
-
Positron emission tomography/computed tomography for bone tumors (Review).Oncol Lett. 2015 Feb;9(2):522-526. doi: 10.3892/ol.2014.2728. Epub 2014 Nov 21. Oncol Lett. 2015. PMID: 25621021 Free PMC article.
-
The metastasectomy and timing of pulmonary metastases on the outcome of osteosarcoma patients.Clin Med Oncol. 2009 Sep 14;3:99-105. doi: 10.4137/cmo.s531. Clin Med Oncol. 2009. PMID: 20689616 Free PMC article.
-
Tumor necrosis in osteosarcoma: inclusion of the point of greatest metabolic activity from F-18 FDG PET/CT in the histopathologic analysis.Skeletal Radiol. 2010 Feb;39(2):131-40. doi: 10.1007/s00256-009-0785-8. Epub 2009 Sep 17. Skeletal Radiol. 2010. PMID: 19760279
-
Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway.BMC Cancer. 2010 May 10;10:187. doi: 10.1186/1471-2407-10-187. BMC Cancer. 2010. PMID: 20459702 Free PMC article.
-
Long-term survivals of stage IIb osteosarcoma: a 20-year experience in a single institution.Clin Orthop Surg. 2011 Mar;3(1):48-54. doi: 10.4055/cios.2011.3.1.48. Epub 2011 Feb 15. Clin Orthop Surg. 2011. PMID: 21369478 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical